BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hsu CY, Wang CW, Cheng AL, Kuo SH. Hypofractionated particle beam therapy for hepatocellular carcinoma–a brief review of clinical effectiveness. World J Gastrointest Oncol 2019; 11(8): 579-588 [PMID: 31435460 DOI: 10.4251/wjgo.v11.i8.579] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Lock M, Chow R, Jayatilaka A, Plotnick M, Stephens R, Nguyen T, Fisher B, Wong E, Gaede S. Does stereotactic body radiation improve outcomes compared to conventional radiation for liver cancer patients? Clinical and Translational Radiation Oncology 2022. [DOI: 10.1016/j.ctro.2022.04.002] [Reference Citation Analysis]
2 Tsai YL, Takei H, Iizumi T, Okumura T, Sekino Y, Numajiri H, Ishikawa H, Sakae T, Sakurai H. Capacity of proton beams in preserving normal liver tissue during proton beam therapy for hepatocellular carcinoma. J Radiat Res 2021;62:133-41. [PMID: 33392617 DOI: 10.1093/jrr/rraa098] [Reference Citation Analysis]
3 Cozzi L, Comito T, Loi M, Fogliata A, Franzese C, Franceschini D, Clerici E, Reggiori G, Tomatis S, Scorsetti M. The Potential Role of Intensity-Modulated Proton Therapy in Hepatic Carcinoma in Mitigating the Risk of Dose De-Escalation. Technol Cancer Res Treat 2020;19:1533033820980412. [PMID: 33287650 DOI: 10.1177/1533033820980412] [Reference Citation Analysis]